FY2024 Earnings Forecast for CNTA Issued By Leerink Partnrs

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) - Equities research analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for shares of Centessa Pharmaceuticals in a report issued on Wednesday, November 20th. Leerink Partnrs analyst D. Risinger now anticipates that the company will earn ($1.56) per share for the year, up from their previous forecast of ($1.65). The consensus estimate for Centessa Pharmaceuticals' current full-year earnings is ($1.62) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals' Q4 2024 earnings at ($0.41) EPS and FY2025 earnings at ($1.50) EPS.

Other equities research analysts also recently issued reports about the stock. Oppenheimer reaffirmed an "outperform" rating and issued a $14.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. BMO Capital Markets boosted their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an "outperform" rating in a research report on Monday, September 16th. Jefferies Financial Group raised their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, September 11th. Guggenheim increased their price objective on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research report on Friday, November 15th. Finally, B. Riley started coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a "buy" rating and a $33.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of "Buy" and an average target price of $25.83.

Centessa Pharmaceuticals Stock Performance

CNTA stock traded down $0.91 during midday trading on Friday, hitting $17.28. The company's stock had a trading volume of 620,973 shares, compared to its average volume of 411,182. Centessa Pharmaceuticals has a 1 year low of $5.58 and a 1 year high of $18.74. The stock's 50-day moving average price is $16.09 and its 200 day moving average price is $12.33. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -11.89 and a beta of 1.47. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC lifted its holdings in shares of Centessa Pharmaceuticals by 68.7% in the third quarter. Geode Capital Management LLC now owns 56,597 shares of the company's stock valued at $905,000 after purchasing an additional 23,058 shares in the last quarter. Jane Street Group LLC acquired a new position in Centessa Pharmaceuticals in the third quarter worth about $2,834,000. Wellington Management Group LLP bought a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter worth approximately $1,609,000. State Street Corp acquired a new position in shares of Centessa Pharmaceuticals during the third quarter worth approximately $777,000. Finally, RTW Investments LP bought a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter worth about $800,000. Institutional investors and hedge funds own 82.01% of the company's stock.

Insider Transactions at Centessa Pharmaceuticals

In related news, CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction on Friday, September 20th. The shares were sold at an average price of $16.53, for a total transaction of $909,150.00. Following the sale, the chief executive officer now directly owns 721,924 shares in the company, valued at $11,933,403.72. This trade represents a 7.08 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gregory M. Weinhoff sold 25,000 shares of Centessa Pharmaceuticals stock in a transaction on Monday, September 9th. The shares were sold at an average price of $15.00, for a total transaction of $375,000.00. Following the completion of the transaction, the insider now owns 223,369 shares in the company, valued at approximately $3,350,535. This represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 308,158 shares of company stock valued at $5,007,043 over the last ninety days. Insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.